JP2019528683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528683A5 JP2019528683A5 JP2019502565A JP2019502565A JP2019528683A5 JP 2019528683 A5 JP2019528683 A5 JP 2019528683A5 JP 2019502565 A JP2019502565 A JP 2019502565A JP 2019502565 A JP2019502565 A JP 2019502565A JP 2019528683 A5 JP2019528683 A5 JP 2019528683A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- sequence
- binding molecule
- gitr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 42
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 6
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 210000003289 regulatory T cell Anatomy 0.000 claims description 5
- 230000002476 tumorcidal effect Effects 0.000 claims description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000005809 anti-tumor immunity Effects 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000005909 tumor killing Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364762P | 2016-07-20 | 2016-07-20 | |
| US62/364,762 | 2016-07-20 | ||
| PCT/US2017/043166 WO2018017889A1 (en) | 2016-07-20 | 2017-07-20 | Multimeric gitr binding molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528683A JP2019528683A (ja) | 2019-10-17 |
| JP2019528683A5 true JP2019528683A5 (enExample) | 2020-08-13 |
Family
ID=60992910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502565A Withdrawn JP2019528683A (ja) | 2016-07-20 | 2017-07-20 | 多量体ｇｉｔｒ結合分子及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190330360A1 (enExample) |
| EP (1) | EP3487299A4 (enExample) |
| JP (1) | JP2019528683A (enExample) |
| CN (1) | CN109561681A (enExample) |
| AU (1) | AU2017300647A1 (enExample) |
| CA (1) | CA3030659A1 (enExample) |
| IL (1) | IL263800A (enExample) |
| MX (1) | MX2019000799A (enExample) |
| WO (1) | WO2018017889A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| EP3105250B1 (en) | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| SG11201809336QA (en) | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| MX2019011986A (es) | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| MX2020009069A (es) * | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| US20210380701A1 (en) * | 2018-10-23 | 2021-12-09 | Igm Biosciences, Inc. | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
| JP2022544405A (ja) | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| EP4139362A2 (en) * | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
| WO2022109023A1 (en) * | 2020-11-17 | 2022-05-27 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
| CN113151186B (zh) * | 2021-02-04 | 2022-02-18 | 上海交通大学 | 抗人cd271的单克隆抗体及用途 |
| US12600801B2 (en) | 2022-07-11 | 2026-04-14 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ROR1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US8658159B2 (en) * | 2008-06-30 | 2014-02-25 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
| NZ590667A (en) * | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| US9382319B2 (en) * | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| US20150038682A1 (en) * | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| TW201605896A (zh) * | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| SI3148579T1 (sl) * | 2014-05-28 | 2021-07-30 | Agenus Inc. | Proti GITR antitelesa in postopki z njihovo uporabo |
| PE20170441A1 (es) * | 2014-06-06 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |
| IL308212A (en) * | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3356401B1 (en) * | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
-
2017
- 2017-07-20 MX MX2019000799A patent/MX2019000799A/es unknown
- 2017-07-20 US US16/317,816 patent/US20190330360A1/en not_active Abandoned
- 2017-07-20 JP JP2019502565A patent/JP2019528683A/ja not_active Withdrawn
- 2017-07-20 AU AU2017300647A patent/AU2017300647A1/en not_active Abandoned
- 2017-07-20 EP EP17831909.1A patent/EP3487299A4/en not_active Withdrawn
- 2017-07-20 CA CA3030659A patent/CA3030659A1/en not_active Abandoned
- 2017-07-20 WO PCT/US2017/043166 patent/WO2018017889A1/en not_active Ceased
- 2017-07-20 CN CN201780045191.5A patent/CN109561681A/zh active Pending
-
2018
- 2018-12-18 IL IL263800A patent/IL263800A/en unknown
-
2022
- 2022-02-24 US US17/680,026 patent/US20220177595A1/en not_active Abandoned